Tirzepatide: Positioned as a dual GIP and GLP-1 receptor agonist, Tirzepatide offers a novel approach to diabetes management
For the most accurate estimates, refresh the GoodRx searches and enter your zip code
Recently, theyve begun issuing warning letters to some pharmacies, giving them a chance to back off from unfounded claims about their drugs
Relevant Research Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomised controlled trials Retatrutide for the treatment of obesity, obstructive sleep apnea, and knee osteoarthritis: rationale and design of the TRIUMPH registrational clinical trials Retatrutidea game changer in obesity pharmacotherapy Unleashing the power of retatrutide: a possible triumph over obesity Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomised phase 2a trial Retatrutide in type 2 diabetes mellitus and obesity: an overview
The break is not required for safety or receptor resensitization, but it allows for reassessment and prevents indefinite use of a compound with limited long-term human data